Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izag051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Maria G Maseng und 21 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Inflammation, Inflammatory Bowel Diseases, Colitis, Ulcerative. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Tillotts Pharma, Foundation Dam, and the Norwegian South-Eastern Health Authorities, NordForsk, Vinnova.
Abstract (Originalsprache)
Background and Aim Despite the well-established involvement of the gut microbiome in inflammatory bowel disease (IBD), less is known about how the gut microbiome changes over time and how it varies with clinical disease activity and fecal calprotectin (f-calprotectin). To address this gap, we utilized samples from the population-based inception cohort of the Inflammatory Bowel Disease in South-Eastern Norway III (IBSEN III) study.
Methods
Data and stool samples from study participants with IBD and symptomatic controls were collected at diagnosis and after 3, 6, and 12 months. Microbiome profiling of stool samples was performed targeting the V3-V4 region of the 16S rRNA gene, and a consensus-based approach of mixed models was employed for the longitudinal microbiome analysis.
Results
We included 1251 samples from 744 patients with ulcerative colitis, 618 samples from 356 patients with Crohn’ s disease and 266 samples from 164 symptomatic non-IBD controls. In the IBD population, we observed that levels of f-calprotectin decreased over time, as did the patient-reported disease activity (P < .001). Distinct changes in the gut microbiome of IBD patients were observed throughout the first year, such as increased alpha diversity (P < .001) and significant taxonomic changes. Notably, there was no covariation between the changes in alpha diversity and f-calprotectin or symptom score.
Conclusion
The gut microbiome during the first year after IBD diagnosis showed changes that paralleled inflammation and clinical disease activity, albeit without covariation, suggesting that there may be a disease-driving impact of gut microbiome independent of inflammation and inflammation-driven symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0371 Oslo, Norway.
- Department of Gastroenterology, Division of Medicine, Oslo University Hospital, 0450 Oslo, Norway.
- Bio-Me AS, 0349 Oslo, Norway.
- Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Norwegian PSC Research Centre, Oslo University Hospital, 0372 Oslo, Norway.
- Division of Surgery, Inflammatory Diseases and Transplantation, Research Institute of Internal Medicine, Oslo University Hospital, 0450 Oslo, Norway.
- Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, 701 82, Sweden.
ORCID-Profile: Maria G Maseng, Simen H Hansen, Corinna Bang, Charlotte Lund, Gert Huppertz-Hauss, Gøri Perminow, Jørgen Valeur, May-Bente Bengtson, Randi Opheim, Raziye Boyar, Svein O Frigstad, Trond Espen Detlie, Vibeke Strande, Øistein Hovde, Andre Franke, Jonas Halfvarsson, Marte L Høivik, Johannes R Hov
Förderung
- Takeda Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Tillotts Pharma, Foundation Dam, and the Norwegian South-Eastern Health Authorities
- NordForsk
- Vinnova
- Research Council of Norway
- Regional Health Authorities South-Eastern Norway
- DFG Excellence Cluster 2167 "Precision Medicine in Chronic Inflammation" (PMI) and the DFG Research Unit 5042 "miTarget"
- The IBSEN III
- Takeda Pharmaceuticals
Zitieren
APA
Maseng, M. G., Hansen, S. H., Grännö, O., Bang, C., Lund, C., Huppertz-Hauss, G., Perminow, G., Valeur, J., Bengtson, M. B., Opheim, R., Boyar, R., Frigstad, S. O., Aabrekk, T. B., Detlie, T. E., Kristensen, V. A., Strande, V., Hovde, Ø., Asak, Ø., Franke, A., …, & Hov, J. R. (2026). Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag051
Vancouver
Maseng MG, Hansen SH, Grännö O, Bang C, Lund C, Huppertz-Hauss G, et al. Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag051
BibTeX
@article{Maseng2026,
author = {Maseng, Maria G and Hansen, Simen H and Grännö, Olle and Bang, Corinna and Lund, Charlotte and Huppertz-Hauss, Gert and Perminow, Gøri and Valeur, Jørgen and Bengtson, May-Bente and Opheim, Randi and Boyar, Raziye and Frigstad, Svein O and Aabrekk, Tone Bergene and Detlie, Trond Espen and Kristensen, Vendel A and Strande, Vibeke and Hovde, Øistein and Asak, Øyvind and Franke, Andre and Halfvarsson, Jonas and Høivik, Marte L and Hov, Johannes R},
title = {Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag051}
}
EUVIMED